ABI
DNDN

Adamant Biomedical Investments’s DENDREON CORPORATION DNDN Stock Holding History

Adamant Biomedical Investments’s Portfolio DNDN Stock Details DNDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-50,000
Closed -$72K – 108
2014
Q3 		$72K Buy
+50,000
New +$87.6K 0.02% 95

Other funds holding DNDN

Norges Bank
Norges Bank Oslo, Norway $935B AUM
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Adamant Biomedical Investments's DNDN Position: Q4 2014 in Review

Adamant Biomedical Investments sold out of DENDREON CORPORATION (DNDN) in Q4 2014, closing a stake of 50,000 shares — an estimated $72K sold.

Adamant Biomedical Investments first reported a position in DNDN in Q3 2014 and held it in 1 quarter. The position peaked at $72K in Q3 2014. 16 funds tracked by Wall St. Rank hold DNDN as of Q4 2014.

  • Adamant Biomedical Investments reported no remaining DENDREON CORPORATION position as of Q4 2014 after selling out during the quarter.
  • Adamant Biomedical Investments sold 50,000 DENDREON CORPORATION shares in Q4 2014, an estimated $72K.
  • Adamant Biomedical Investments first reported a position in DENDREON CORPORATION in Q3 2014 and held it in 1 quarter.
  • Adamant Biomedical Investments's DENDREON CORPORATION position peaked at $72K in Q3 2014.
  • 16 funds tracked by Wall St. Rank held DENDREON CORPORATION as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.